Posted by Michael Wonder on 12 Aug 2021
Thousands of south Aucklanders could benefit from Medsafe approving new diabetes drug
12 August 2021 - Medsafe’s approval of a new drug for type 2 diabetes could dramatically change the lives of thousands of people in south Auckland, according to Diabetes Foundation Aotearoa.
PHARMAC approved funding for empagliflozin and dulaglutide for 53,000 patients with the disease who met certain criteria in December.
But the funding for dulaglutide was dependent on Medsafe approving the use of the medicine.
